Clinnova-MS: a Prospective Cohort Study of Patients With Multiple Sclerosis A Trans-Regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care (Switzerland)

What this Trial Is About

This research aims to better understand Multiple Sclerosis (MS), a chronic condition affecting the nervous system that causes symptoms like cognitive issues, fatigue, vision problems, and muscle weakness. The study focuses on patients with early MS or those moving into progressive phases. It seeks to identify clinical, imaging, and biological markers linked to different stages of MS and to explore digital tools for continuous monitoring of patients as part of the Clinnova programme. Participants with MS will be followed over several years. They will be assessed annually, with an optional 6-month check, and continuously use the Healios+Me smartphone app for digital health measurements. Data collected will include clinical exams, patient-reported outcomes, cognitive and motor tests, biological samples, and imaging data when available. The study includes a long-term follow-up extending up to five years, offering detailed tracking of disease progression and patient function. During the study, participants will attend scheduled visits at baseline, 6 months (optional), and annually for up to five years. Assessments include neurological tests, cognitive evaluations, vision tests, and questionnaires on symptoms, fatigue, mood, and quality of life. Biological samples like blood and cerebrospinal fluid may be collected. Researchers will analyze these data to find biomarkers that better describe MS progression and support treatment decisions. The study is sponsored by University Hospital Basel and aims to enroll around 800 patients across multiple centers.

Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)